Literature DB >> 23444052

Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.

Y Shibata1, K Suzuki, S Arai, Y Miyoshi, S Umemoto, N Masumori, N Kamiya, T Ichikawa, Y Kitagawa, A Mizokami, Y Sugimura, N Nonomura, H Sakai, S Honma, Y Kubota.   

Abstract

Great advances in tissue androgen analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS) have made it possible to evaluate the tissue androgen content from a single needle prostate biopsy specimen. In this study, we investigated if pre-treatment androgen content in prostate biopsy specimens could predict their response to primary androgen deprivation therapy (ADT) and future castration-resistant prostate cancer (CRPC). One-hundred and sixty-five prostate cancer patients who received primary ADT were enrolled. They had received multiple core prostate needle biopsy at diagnosis, and an additional one needle biopsy specimen was obtained for tissue androgen determination using LC-MS/MS. The patients' prostate specific antigen (PSA) values were periodically followed during the treatment and patients were determined to have CRPC when their PSA value increased continuously to 25% above the nadir and a 2.0 ng/mL increase. A significant correlation was found between PSA value decline velocity (PSA half-time) after ADT and pre-ADT tissue androgen content. Twenty-three patients were determined to have CRPC. These CRPC patients had a significantly high concentration of tissue T (p < 0.01) and low concentration of tissue 5α-dihydrotestosterone (DHT) (p < 0.01), resulting in a higher tissue T/DHT ratio (p < 0.001). A multivariate Cox proportional hazard model revealed the pre-ADT tissue T/DHT ratio and Gleason score as independent predictors for CRPC development. By using the two statistically significant variables, the relative risk of CRPC development could be calculated. The results of this study suggest that the evaluation of prostate androgen content in a single needle biopsy specimen may be useful to predict future CRPC development after primary ADT. Further studies are required for the clinical application of T/DHT ratio evaluation.
© 2013 American Society of Andrology and European Academy of Andrology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23444052     DOI: 10.1111/j.2047-2927.2013.00068.x

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  4 in total

1.  HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.

Authors:  I-Ju Yeh; Kyung Song; Bryan M Wittmann; Xiaodong Bai; David Danielpour; Monica M Montano
Journal:  Biochem J       Date:  2014-09-01       Impact factor: 3.857

2.  Steroid hormone synthetic pathways in prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Transl Androl Urol       Date:  2013-09

3.  High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.

Authors:  Yasuhide Miyoshi; Hiroji Uemura; Susumu Umemoto; Kentaro Sakamaki; Satoshi Morita; Kazuhiro Suzuki; Yasuhiro Shibata; Naoya Masumori; Tomohiko Ichikawa; Atsushi Mizokami; Yoshiki Sugimura; Norio Nonomura; Hideki Sakai; Seijiro Honma; Masaoki Harada; Yoshinobu Kubota
Journal:  BMC Cancer       Date:  2014-09-26       Impact factor: 4.430

4.  Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy.

Authors:  Agus Rizal A H Hamid; Harun W Kusuma Putra; Ningrum Paramita Sari; Putri Diana; Saras Serani Sesari; Eka Novita; Fajar Lamhot Gultom; Meilania Saraswati; Budiana Tanurahardja; Rainy Umbas; Chaidir A Mochtar
Journal:  BMC Urol       Date:  2020-06-19       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.